我院住院药房2009～2010年免疫增强剂用药分析  

Analysis of immunopotentiator application in pharmacy department of our hospital from 2009 to 2010

作　　者：陈世灵[1,2] 王娟娟[1,2] 张勤勇[1,2] 

机构地区：[1]昆明医学院第三附属医院 [2]云南省肿瘤医院药剂科,云南昆明650118

出　　处：《中国医药导报》2012年第2期126-127,共2页China Medical Herald

摘　　要：目的分析我院免疫增强剂销售金额、用药构成比以及DDDs排序,了解用药现状,为临床治疗提供参考。方法对我院住院药房2009-2010年免疫增强剂销售金额、用药构成比以及DDDs排序进行统计比较分析。结果我院免疫增强剂的用药金额呈逐年上升趋势,从用药构成比及DDDs排序来看,胸腺肽制剂居第1位,2009~2010年DDDs排序无明显变化。结论我院免疫增强剂销售金额增长稳定,胸腺肽制剂居第1位,是免疫增强剂的用药主体,免疫增强剂用药基本合理。Objective To analyze the sales amounts,drug constituent ratio and DDDs sort of immunopotentiator,understand the present situation of drug application,in order to provide reference for clinical treatment.Methods The sales amounts,drug constituent ratio and DDDs sort of immunopotentiator in pharmacy department of our hospital from 2009 to 2010 were compared and analyzed.Results The sales amounts of immunopotentiator drug in our hospital increased year by year,the drug constituent ratio and DDDs sort of thymosin preparation were taken the first place.DDDs sort had no significant change from 2009 to 2010.Conclusion The sales amounts of immunopotentiator increases steadily in our hospital,thymosin preparation is taken the first place,which is the main subject of immunopotentiator drug application.The application of immunopotentiator in our hospital is reasonable basically.

关 键 词：免疫增强剂 销售金额 构成比 DDDS排序 用药现状 

分 类 号：R73[医药卫生—肿瘤]